Effect of simvastatin on the antihypertensive activity of losartan in hypertensive hypercholesterolemic animals and patients: Role of nitric oxide, oxidative stress, and high-sensitivity C-reactive protein

Fundamental and Clinical Pharmacology

Volumn 28, Issue 3, 2014, Pages 237-248

  Abdel Zaher, Ahmed O ^a   Elkoussi, Alaa Eldin A ^a   Abudahab, Lotfy H ^b   Elbakry, Mohammed H ^c   Elsayed, Elsayed Abu Elwafa ^c  

^a Assiut University Faculty of Medicine   (Egypt)

^b Sohag University   (Egypt)

^c AL AZHAR UNIVERSITY   (Egypt)

Author keywords

Endothelial dysfunction; Losartan; Oxidative stress; Simvastatin

Indexed keywords

ANTIHYPERTENSIVE AGENT; C REACTIVE PROTEIN; HYPOCHOLESTEROLEMIC AGENT; LOSARTAN; NITRIC OXIDE; SIMVASTATIN;

ADULT; AGED; ANIMAL; AORTA; BLOOD PRESSURE; CLINICAL TRIAL; COMPLICATION; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECTS; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IN VITRO STUDY; MALE; METABOLISM; MIDDLE AGED; MUSCLE ISOMETRIC CONTRACTION; OXIDATIVE STRESS; RABBIT; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM; WISTAR RAT;

ADULT; AGED; ANIMALS; ANTICHOLESTEREMIC AGENTS; ANTIHYPERTENSIVE AGENTS; AORTA; BLOOD PRESSURE; C-REACTIVE PROTEIN; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; IN VITRO TECHNIQUES; ISOMETRIC CONTRACTION; LOSARTAN; MALE; MIDDLE AGED; NITRIC OXIDE; OXIDATIVE STRESS; RABBITS; RATS, WISTAR; SIMVASTATIN; TREATMENT OUTCOME;

EID: 84899083327     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/fcp.12020     Document Type: Article

References (45)

1. Koh K.K., Oh P.C., Quon M.J. Does reversal of oxidative stress and inflammation provide vascular protection? Cardiovasc. Res. (2009) 81 649-659.
2. Ghiadoni L., Taddei S., Virdis A. Hypertension and endothelial dysfunction: therapeutic approach. Curr. Vasc. Pharmacol. (2012) 10 42-60.
3. Chang L., Sun C., Chiang C., Wu C., Chua S., Yip H. Impact of simvastatin and losartan on antiinflammatory effect: in vitro study. J. Cardiovasc. Pharmacol. (2007) 49 20-26.
4. Fiorentino A.D., Cianchetti S., Celi A., Dell'Omo G., Pedrinelli A. The effect of angiotensin receptor blockers on C-reactive protein and other circulating inflammatory indices in man. Vasc. Health Risk Manag. (2009) 5 233-242.
5. Zhou Q., Liao J.K. Pleiotropic effects of statins. Circ. J. (2010) 74 818-826.
6. Zhang Z., Wang M., Xue S.J., Liu D.H., Tang Y.B. Simvastatin ameliorates angiotensin II-induced endothelial dysfunction through restoration of Rho-BH4-eNOS-NO pathway. Cardiovasc. Drugs Ther. (2012) 26 31-40.
7. Won Suh J., Ju Choi D., Jae Chang H. et al. HMG-CoA reductase inhibitor improves endothelial dysfunction in spontaneous hypertensive rats via down-regulation of caveolin-1 and activation of endothelial nitric oxide synthase. J. Korean Med. Sci. (2010) 25 16-23.
8. Paulsen P. Statins and inflammation: an update. Curr. Opin. Cardiol. (2010) 23 243-275.
9. Calza L., Trapani F., Bartoletti M. et al. Statin therapy decreases serum levels of high-sensitivity C-reactive protein and tumor necrosis factor-α in HIV-infected patients treated with ritonavir-boosted protease inhibitors. HIV Clin. Trials (2012) 13 153-161.
10. Seo H.S. The role and clinical significance of high-sensitivity C-reactive protein in cardiovascular disease. Korean Circ. J. (2012) 42 151-153.
11. Tunon J., Martin-Ventura J., Blanco-Colio L.M., Tarin N., Egido J. Common pathways of hypercholesterolemia and hypertension leading to atherothrombosis: the need for a global approach in the management of cardiovascular risk factors. Vasc. Health Risk Manag. (2007) 3 521-526.
12. Harrison D., Griendling K.K., Landmesser U., Hornig B., Drexler H. Role of oxidative stress in atherosclerosis. Am. J. Cardiol. (2003) 91 7-11.
13. Kuzelova M., Adameova A., Sumbalova Z. et al. The effect of simvastatin on coenzyme Q and antioxidant/oxidant balance in diabetic-hypercholesterolaemic rats. Gen. Physiol. Biophys. (2008) 27 291-298.
14. Tonelli M., Sacks F., Pfeffer M., Lopez-Jimenez F., Jhangri G.S., Curhan G. Effect of pravastatin on blood pressure in people with cardiovascular disease. J. Hum. Hypertens. (2006) 20 560-565.
15. Koh K.K., Michael J., Quon M.J., Myron A. Are statins effective for simultaneously treating dyslipidemias and hypertension? Atherosclerosis (2008) 196 1-8.
16. Stepien M., Banach M., Mikhailidis D.P., Gluba A., Kjeldsen S.E., Rysz J. Role and significance of statins in the treatment of hypertensive patients. Curr. Med. Res. Opin. (2009) 25 1995-2005.
17. Mancia G., Parati G., Revera M. et al. Statins, antihypertensive treatment, and blood pressure control in clinic and over 24 hours: evidence from PHYLLIS randomised double blind trial. BMJ (2010) 340 1197-1201.
18. Owczarek J., Jasińska M., Wejman I., Kurczewska U., Orszulak-Michalak D. Effects of 4-week administration of simvastatin in different doses on heart rate and blood pressure after metoprolol injection in normocholesterolaemic and normotensive rats. Arch. Med. Sci. (2012) 29 17-21.
19. Ribeiro M.O., Antunes E., de Nucci G., Lovisolo S.M., Zatz R. Chronic inhibition of nitric oxide synthesis. A new model of arterial hypertension. Hypertension (1992) 20 298-303.
20. Rauchova H., Ova O.P., Kunes J., Vokurkova M., Ova Z.D., Zicha J. Chronic N-acetylcysteine administration prevents development of hypertension in L-nitro-L-arginine methyl ester-treated rats: the role of reactive oxygen species. Hypertens. Res. (2005) 28 475-482.
21. Angelo E., Rossi P., Tanzi F., Taglietti V. Induction of hypercholesterolemia and mechanism of protection against atherosclerosis. Am. J. Cardiol. (1992) 9 823-831.
22. Friedwald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of LDL-C in plasma without use of preparative ultra-centrifuge. Clin. Chem. (1972) 18 499-502.
23. Miranda K.M., Espey M.G., Wink D.A. A rapid, simple spectrophotometric method for simultaneous detection of nitrate and nitrite. Nitric Oxide (2001) 5 62-71.
24. Ohkawa H., Ohishi N., Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. (1979) 95 351-358.
25. Roberts W.L., Moulton L., Law T.C. et al. Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Clin. Chem. (2001) 47 418-425.
26. Schmieder R.E., Ruilope L.M. Blood pressure control in patients with comorbidities. J. Clin. Hypertens. (2008) 10 624-631.
27. Wang C.H., Li S.H., Weisel R.D. et al. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation (2003) 107 1783-1790.
28. Vermas S., Wang C.H., Li S.H. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation (2002) 106 913-919.
29. Liu P.Y., Liu Y.W., Lin L.J., Chen J.H., Liao J.K. Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. Circulation (2009) 119 131-138.
30. Delbosc S., Cristol J., Descomps B., Mimran A., Jover B. Simvastatin prevents angiotensin II-induced cardiac alteration and oxidative stress. Hypertension (2002) 40 142-148.
31. Kanbay M., Yildirir A., Bozbas H. et al. Statin therapy helps to control blood pressure levels in hypertensive dyslipidemic patients. Ren. Fail. (2005) 27 297-303.
32. Leibovitz E., Hazanov N., Zimlichman R., Shargorodsky M., Gavish D. Treatment with atorvastatin improves small artery compliance in patients with severe hypercholesterolemia. Am. J. Hypertens. (2001) 14 1096-1098.
33. Terzoli L., Mircoli L., Raco R., Ferrari A.U. Lowering of elevated ambulatory blood pressure by HMG-CoA reductase inhibitors. J. Cardiovasc. Pharmacol. (2005) 46 310-315.
34. Koh K.K., Quon M.J., Han S.H., Chung W.J., Lee Y., Shin E.K. Anti-inflammatory and metabolic effects of candesartan in hypertensive patients. Int. J. Cardiol. (2006) 108 96-100.
35. Mason R.P., Jacob R.F., Kubant R. et al. Effects of angiotensin receptor blockers on endothelial nitric oxide release - The role of eNOS variants. Br. J. Clin. Pharmacol. (2012) 74 141-146.
36. Rajagopalan S., Zannad F., Radauceanu A., Pitt B. A multicenter double-blind randomized controlled trial of a statin + angiotensin receptor blockade combination in patients with hypertension and concomitant hyperlipidemia. Circulation (2004) 110 397-402.
37. Ikeda T., Sakurai J., Nakayama D. et al. Pravastatin has an additional depressor effect in patients undergoing long-term treatment with antihypertensive drugs. Am. J. Hypertens. (2004) 17 502-506.
38. Borghi C., Prandin M.G., Costa F.V., Bacchelli S., Degli Esposti D., Ambrsioni E. Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia. J. Cardiovasc. Pharmacol. (2000) 35 549-555.
39. Abdel-Zaher A.O., Elkoussi A.A., Abudahab L.H., Elbakry M.H., Elsayed E.A. Simvastatin enhances the antihypertensive effect of ramipril in hypertensive hypercholesterolemic animals and patients. Possible role of nitric oxide, oxidative stress and high sensitivity C-reactive protein. Fundam. Clin. Pharmacol. (2012) 26 701-711.
40. Han S.H., Koh K.K., Quon M.J., Lee Y., Shin E.K. The effects of simvastatin, losartan, and combined therapy on soluble CD40 ligand in hypercholesterolemic, hypertensive patients. Atherosclerosis (2007) 190 205-211.
41. Sohma R., Inoue T., Abe S. et al. Cardioprotective effects of low-dose combination therapy with a statin and an angiotensin receptor blocker in a rat myocardial infarction model. J. Cardiol. (2012) 59 91-96.
42. Brosnan C.F., Battistini L., Raine C.S., Dickson D.W., Vall A., Lee S.C. Reactive nitrogen intermediates in human neuropathology. An overview. Dev. Neurosci. (1994) 16 152-161.
43. Knowles R.G., Moncada S. Nitric oxide as a signal in blood vessels. Trends Biochem. Sci. (1992) 17 399-402.
44. Rees D.D., Palmer R.M., Schulz R., Hodson H.F., Moncada S. Characterization of three inhibition of endothelial nitric oxide synthase in vitro and in vivo. Br. J. Pharmacol. (1990) 101 746-752.
45. Ortiz M.C., Fortepiani L.A., Martinez-Salgado C. et al. Renal effects of the chronic inhibition of nitric oxide synthesis in cirrhotic rats with ascites. Nefrologia (2001) 21 556-564.